|
|
Article: Inflazyme Dropping 'Not Core' GH9001 Due To Liver Enzymes.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Redirecting its resources toward core anti-inflammatory programs, Inflazyme Pharmaceuticals Inc. dropped development of an antithrombotic agent when it showed an increase in liver enzymes in a Phase Ib trial.
GH9001, the most advanced product from Inflazyme's acquisition of GlycoDesign Inc., will no longer be studied with partner Leo Pharma.
Elevated liver enzymes are seen in other heparin products, said Ian McBeath, president and CEO of Vancouver, British Columbia-based Inflazyme, and the company "could continue to work with this compound to potentially resolve the safety concern." But he said the reason for not pursuing it further ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|